The concept of treatment-free remission in chronic myeloid leukemia

Autor Saußele, S, Richter, J, Hochhaus, A, Mahon, F-X
Vydáno v Leukemia (2016)

PI3K/mTOR pathway inhibitors sensitize chronic myeloid leukemia stem cells to nilotinib and restore the response of progenitors to nilotinib in the presence of stem cell factor

Autor Airiau, K, Mahon, F-X, Josselin, M, Jeanneteau, M, Belloc, F
Vydáno 2013

GILZ inhibits the mTORC2/AKT pathway in BCR-ABL(+) cells

Autor Joha, S, Nugues, A-L, Hétuin, D, Berthon, C, Dezitter, X, Dauphin, V, Mahon, F-X, Roche-Lestienne, C, Preudhomme, C, Quesnel, B, Idziorek, T
Vydáno 2012

Apoptosis and autophagy have opposite roles on imatinib-induced K562 leukemia cell senescence

Autor Drullion, C, Trégoat, C, Lagarde, V, Tan, S, Gioia, R, Priault, M, Djavaheri-Mergny, M, Brisson, A, Auberger, P, Mahon, F-X, Pasquet, J-M
Vydáno 2012

Low incidence of peripheral arterial disease in patients receiving dasatinib in clinical trials

Autor le Coutre, P D, Hughes, T P, Mahon, F-X, Kim, D-W, Steegmann, J L, Shah, N P, Gooden, K, Wallis, N, Cortes, J E
Vydáno v Leukemia (2016)

A phase 2 study of MK-0457 in patients with BCR-ABL T315I mutant chronic myelogenous leukemia and philadelphia chromosome-positive acute lymphoblastic leukemia

Autor Seymour, J F, Kim, D W, Rubin, E, Haregewoin, A, Clark, J, Watson, P, Hughes, T, Dufva, I, Jimenez, J L, Mahon, F-X, Rousselot, P, Cortes, J, Martinelli, G, Papayannidis, C, Nagler, A, Giles, F J
Vydáno v Blood Cancer J (2014)

Proposed diagnostic criteria and classification of basophilic leukemias and related disorders

Autor Valent, P, Sotlar, K, Blatt, K, Hartmann, K, Reiter, A, Sadovnik, I, Sperr, WR, Bettelheim, P, Akin, C, Bauer, K, George, TI, Hadzijusufovic, E, Wolf, D, Gotlib, J, Mahon, F-X, Metcalfe, DD, Horny, H-P, Arock, M
Vydáno v Leukemia (2017)

Sustained deep molecular responses in patients switched to nilotinib due to persistent BCR-ABL1 on imatinib: final ENESTcmr randomized trial results

Autor Hughes, T P, Leber, B, Cervantes, F, Spector, N, Pasquini, R, Clementino, N C D, Schwarer, A P, Dorlhiac-Llacer, P E, Mahon, F-X, Rea, D, Guerci-Bresler, A, Kamel-Reid, S, Bendit, I, Acharya, S, Glynos, T, Dalal, D, Branford, S, Lipton, J H
Vydáno v Leukemia (2017)

Frontline nilotinib in patients with chronic myeloid leukemia in chronic phase: results from the European ENEST1st study

Autor Hochhaus, A, Rosti, G, Cross, N C P, Steegmann, J L, le Coutre, P, Ossenkoppele, G, Petrov, L, Masszi, T, Hellmann, A, Griskevicius, L, Wiktor-Jedrzejczak, W, Rea, D, Coriu, D, Brümmendorf, T H, Porkka, K, Saglio, G, Gastl, G, Müller, M C, Schuld, P, Di Matteo, P, Pellegrino, A, Dezzani, L, Mahon, F-X, Baccarani, M, Giles, F J
Vydáno v Leukemia (2016)

Increased proportion of mature NK cells is associated with successful imatinib discontinuation in chronic myeloid leukemia

Autor Ilander, M, Olsson-Strömberg, U, Schlums, H, Guilhot, J, Brück, O, Lähteenmäki, H, Kasanen, T, Koskenvesa, P, Söderlund, S, Höglund, M, Markevärn, B, Själander, A, Lotfi, K, Dreimane, A, Lübking, A, Holm, E, Björeman, M, Lehmann, S, Stenke, L, Ohm, L, Gedde-Dahl, T, Majeed, W, Ehrencrona, H, Koskela, S, Saussele, S, Mahon, F-X, Porkka, K, Hjorth-Hansen, H, Bryceson, Y T, Richter, J, Mustjoki, S
Vydáno v Leukemia (2017)

Delayed care for patients with newly diagnosed cancer due to COVID-19 and estimated impact on cancer mortality in France

Autor Blay, J.Y., Boucher, S., Le Vu, B., Cropet, C., Chabaud, S., Perol, D., Barranger, E., Campone, M., Conroy, T., Coutant, C., De Crevoisier, R., Debreuve-Theresette, A., Delord, J.P., Fumoleau, P., Gentil, J., Gomez, F., Guerin, O., Jaffré, A., Lartigau, E., Lemoine, C., Mahe, M.A., Mahon, F.X., Mathieu-Daude, H., Merrouche, Y., Penault-Llorca, F., Pivot, X., Soria, J.C., Thomas, G., Vera, P., Vermeulin, T., Viens, P., Ychou, M., Beaupere, S.
Vydáno v ESMO Open (2021)

European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia

Autor Hochhaus, A., Baccarani, M., Silver, R. T., Schiffer, C., Apperley, J. F., Cervantes, F., Clark, R. E., Cortes, J. E., Deininger, M. W., Guilhot, F., Hjorth-Hansen, H., Hughes, T. P., Janssen, J. J. W. M., Kantarjian, H. M., Kim, D. W., Larson, R. A., Lipton, J. H., Mahon, F. X., Mayer, J., Nicolini, F., Niederwieser, D., Pane, F., Radich, J. P., Rea, D., Richter, J., Rosti, G., Rousselot, P., Saglio, G., Saußele, S., Soverini, S., Steegmann, J. L., Turkina, A., Zaritskey, A., Hehlmann, R.
Vydáno v Leukemia (2020)

Asciminib in Chronic Myeloid Leukemia after ABL Kinase Inhibitor Failure

Autor Hughes, T.P., Mauro, M.J., Cortes, J.E., Minami, H., Rea, D., DeAngelo, D.J., Breccia, M., Goh, Y.-T., Talpaz, M., Hochhaus, A., le Coutre, P., Ottmann, O., Heinrich, M.C., Steegmann, J.L., Deininger, M.W.N., Janssen, J.J.W.M., Mahon, F.-X., Minami, Y., Yeung, D., Ross, D.M., Tallman, M.S., Park, J.H., Druker, B.J., Hynds, D., Duan, Y., Meille, C., Hourcade-Potelleret, F., Vanasse, K.G., Lang, F., Kim, D.-W.
Vydáno v N Engl J Med (2019)

Development and evaluation of a secondary reference panel for BCR-ABL1 quantification on the International Scale

Autor Cross, N C P, White, H E, Ernst, T, Welden, L, Dietz, C, Saglio, G, Mahon, F-X, Wong, C C, Zheng, D, Wong, S, Wang, S-S, Akiki, S, Albano, F, Andrikovics, H, Anwar, J, Balatzenko, G, Bendit, I, Beveridge, J, Boeckx, N, Cerveira, N, Cheng, S-M, Colomer, D, Czurda, S, Daraio, F, Dulucq, S, Eggen, L, El Housni, H, Gerrard, G, Gniot, M, Izzo, B, Jacquin, D, Janssen, J J W M, Jeromin, S, Jurcek, T, Kim, D-W, Machova-Polakova, K, Martinez-Lopez, J, McBean, M, Mesanovic, S, Mitterbauer-Hohendanner, G, Mobtaker, H, Mozziconacci, M-J, Pajič, T, Pallisgaard, N, Panagiotidis, P, Press, R D, Qin, Y-Z, Radich, J, Sacha, T, Touloumenidou, T, Waits, P, Wilkinson, E, Zadro, R, Müller, M C, Hochhaus, A, Branford, S
Vydáno v Leukemia (2016)